Article Sidebar

pdf
Date Published: 04/11/2025
Abstract Views: 170
Views pdf: 71
DOI: https://doi.org/10.51298/vmj.v555i2.16020
Issue
Vol. 555 No. 2 (2025)
Section
Các bài báo
How to Cite
Trần, H. Y., Hồ, H. T., & Dương, Q. H. (2025). CORRELATION BETWEEN SEPTIN9 GENE METHYLATION IN PLASMA AND TUMOR TISSUE SAMPLES IN HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 555(2). https://doi.org/10.51298/vmj.v555i2.16020

CORRELATION BETWEEN SEPTIN9 GENE METHYLATION IN PLASMA AND TUMOR TISSUE SAMPLES IN HEPATOCELLULAR CARCINOMA

Hải Yến Trần, Hữu Thọ Hồ, Quang Huy Dương

Main Article Content

Abstract

Objective: To evaluate the correlation between SEPTIN9 gene methylation (mSEPT9) in plasma samples and tumor tissue samples in patients with hepatocellular carcinoma (HCC). Subjects and Methods: A cross-sectional descriptive study was conducted on 58 patients diagnosed with HCC according to the 2020 guidelines of the Vietnamese Ministry of Health. The study was carried out at the 103 Military Hospital from January 2021 to June 2024. Plasma and tumor tissue mSEPT9 levels were analyzed using semi-nested PCR. Results: The median (interquartile range) delta Ct value of mSEPT9 in tumor tissue was 9.20 (6.74 - 16.88), significantly lower than that in plasma samples, which was 22.93 (13.77 – 26.82), p < 0.0001. A moderate positive correlation was observed between mSEPT9 levels in plasma and tumor tissue samples (r = 0.33, p = 0.01). Stronger correlations were found in specific subgroups: tumors larger than 50 mm (r = 0.53; p = 0.01), tumors involving both liver lobes (r = 0.80; p = 0.02), and patients in BCLC stages B/C/D (r = 0.58; p = 0.01). Conclusion: Plasma mSEPT9 levels are associated with mSEPT9 levels in tumor tissue, particularly in patients with large tumors (> 50 mm), bilobar lesions, and advanced BCLC stages (B/C/D).

Article Details

Keywords

SEPTIN9 gene methylation, hepatocellular carcinoma, liquid biopsy.

References

Filho A.M., Laversanne M., Ferlay J. et al. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer, 156 (7), 1336-1346.
2. Bộ Y tế (2020). Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Quyết định số 3129/QĐ-BYT.
3. Galle P.R., Foerster F., Kudo M. et al. (2019). Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 39 (12), 2214-2229.
4. Villanueva A., Portela A., Sayols S. et al. (2015). DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 61 (6), 1945-1956.
5. Huang F., Yang G., Jiang H. et al. (2022). Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma. Technol Cancer Res Treat, 21, 15330338221144510.
6. Park B.V., Gaba R.C., Huang Y.H. et al. (2019). Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes. J Clin Imaging Sci, 9, 52.
7. Kotoh Y., Suehiro Y., Saeki I. et al. (2020). Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun, 4 (3), 461-470.
8. Wang D., Hu X., Long G. et al. (2019). The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med, 7 (22), 650.